Moderna on Wednesday reported positive early results for its booster shot against new variants of the COVID-19 strains B.1.351 and P.1, which have been identified in South Africa and Brazil, in an ongoing clinical trial.
According to CNBC, Moderna CEO Stephane Bancel said, “As we seek to defeat the ongoing pandemic, we remain committed to being proactive as the virus evolves. We are encouraged by this new data, which reinforces our confidence that our booster strategy should be protective against these newly detected variants.”
The company also said its booster for another vaccine, mRNA-1273.351, had worked even better than its current vaccine against the South African variant, B.1.351. The new booster vaccine is variant-specific and targeted for B.1.351. Results did not trigger an adverse immune response, but there were still side effects associated with its “second dose” vaccine. The Moderna vaccine requires two shots given four weeks apart.
Read more at NEWSMAX.
{Matzav.com}
The current vaccine works quite well against all of these variants. The only reason for the booster would be to boost the money coming in to Moderna and Pfizer.